At the end of this learning unit, the student is able to :
|1||The major objective of this course is to provide students with the required bases to evaluate drug toxicity, the term "drug" being taken in its broader signification including medicines as well as illicit substances and fugi.|
The contribution of this Teaching Unit to the development and command of the skills and learning outcomes of the programme(s) can be accessed at the end of this sheet, in the section entitled “Programmes/courses offering this Teaching Unit”.
The mixed team of teachers from the academic and clinical worlds allows -through "capita selecta"- to cover different target organs with their molecular and cellular specificities but also to address clinical aspects (diagnostic and prognosis in particular).
P. Hantson and X. Wittebole: From clinical cases, the mechanisms of toxic neurological, cardiac and renal manifestations will be discussed for various pharmacological compounds or substances present in the environment.
P. Lysy: Topics will include one or several aspects of the following: (i) endocrinological complications of anti-cancer treatments (chemo + radio), long-term effects of growth hormone therapy, acute / chronic complications of anti-diabetic treatments and drug-induced doping. hormones.
O. Feron: A reflection on the toxicity of anticancer drugs will be conducted through the example of the clinical failure of anti-angiogenic drugs.
Due to the COVID-19 crisis, the information in this section is particularly likely to change.Lectures (classroom and/or remote).
Due to the COVID-19 crisis, the information in this section is particularly likely to change.Questions requiring short-open-responses.